-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Englitazone net SGLT2 inhibitors belong to a new generation, in August 2014 by the US Food and Drug Administration Bureau ( the FDA ) approved after September 2017 approved the listing in mainland China
Manage FDA diabetes
Unlike other oral drugs currently used to treat type II diabetes, Enge's first column is the net SGLT2 class of antidiabetic agents complete heart blood vessels prognosis, it is the only one oral hypoglycemic agents were studied confirmed sugar control, The four-fold curative effect of protecting the heart, protecting the kidney and reducing weight
Engel is the first column net SGLT2 class of antidiabetic drugs only complete cardiac vascular prognosis, it is the only one oral hypoglycemic agents have been shown to control sugar research, protect the heart, kidneys, and quadruple the effect of weight loss
Because SGLT2 inhibitors can lower glucose levels and regulate energy metabolism, some researchers have hypothesized that SGLT2 inhibitors may be a pharmacological method to reverse insulin resistance in the brain and have carried out corresponding studies.
In this randomized, double-blind, placebo-controlled clinical trial, 40 prediabetes patients (60±9 years old; BMI 31.
It turns out that there is a significant interaction between time and treatment in the response of the hypothalamus to insulin
Post-mortem analysis showed that only patients treated with empagliflozin had an increase in hypothalamic insulin responsiveness
The effect of Enpagliflozin on systemic insulin sensitivity (M value under high insulin conditions [40 IU/m2 body surface area/min]
This result confirms insulin resistance in the hypothalamus of human prediabetic patients
Treatment with empagliflozin for 8 weeks can restore hypothalamic insulin sensitivity, which is a favorable response and may contribute to the beneficial effects of SGLT2 inhibitors
In summary, SGLT2 inhibitors are the first drugs to reverse brain insulin resistance and have potential benefits for fat and systemic metabolism
references:
Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.
Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.
Leave a message here